SVB Securities analyst Thomas Smith reiterated a Hold rating on Landos Biopharma (LABP – Research Report) on November 10 and set a price target of $2.00. The company’s shares closed last Friday at $0.27.
According to TipRanks, Smith is an analyst with an average return of -2.4% and a 42.97% success rate. Smith covers the Healthcare sector, focusing on stocks such as Keros Therapeutics, MannKind, and Immunic.
Currently, the analyst consensus on Landos Biopharma is a Hold with an average price target of $2.00.
See Insiders’ Hot Stocks on TipRanks >>
Based on Landos Biopharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $11.28 million. In comparison, last year the company earned a revenue of $18 million and had a net profit of $4.1 million
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LABP in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. The LANCE platform identifies novel therapeutic targets based on predictions of immunometabolic function and creates therapeutic candidates to engage those targets in areas of unmet medical need.
Read More on LABP:
